Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes (METTSEO)

Phase: Recruiting

Condition(s): Ewing Sarcoma

NCT Number: NCT07194044 Other Study ID Number(s): MCC 23281

What Is the Purpose of This Study?

This study will test the safety and feasibility of a new treatment regimen that uses chemotherapy drugs that are already known to be effective against Ewing sarcoma but delivers them in a new way. Instead of repeating the same standard treatment over many cycles, the combinations of drugs will be changed more frequently to help prevent the cancer from becoming resistant, while also aiming to reduce side effects and improve quality of life. The study will also collect blood, imaging, and tissue samples to better understand how the cancer responds to treatment and why certain approaches may be more effective than others.

 

Who Can Take Part in This Study?

 People who may be eligible for this study:

  • Patients with newly diagnosed, widely metastatic Ewing sarcoma or CIC-rearranged sarcoma
  • Are over age 1 year

View full eligibility requirements for this clinical trial.

 

What Will Happen During This Study?

  • Patients will receive various chemotherapy drugs for 38 weeks, with the combination of drugs changing every 6-8 weeks.
  • Patients will then be given maintenance therapy for up to 66 additional weeks.
  • Blood, imaging, and, in some cases, tumor tissue will be collected.

Principal Investigator

Bhuvana A. Setty
MD

Hematology & Oncology

Discover More Research
Explore additional studies relating to sarcoma and solid tumors